Last updated: February 16, 2026
Overview
NDC 25021-0102 pertains to bupivacaine hydrochloride, a local anesthetic mainly used in surgical procedures, obstetrics, and pain management. The product's primary formulation is a 0.25% solution, supplied in single-dose vials.
Market Landscape
-
Market Size: The global local anesthetic market was valued at approximately $2.8 billion in 2022, with growth driven by increasing surgical procedures and outpatient procedures.
-
Key Players: Major competitors include Hospira (Pfizer), I-Flow Corporation, and Teleflex. Hospira's Bupivacaine HCl remains the dominant product in the U.S. market.
-
Market Share: Hospira’s bupivacaine holds roughly 60-70% of the U.S. market, with other brands and compounded products covering the remainder.
-
Regulatory Status: The drug is FDA-approved, with supplemental indications approved over the years. The product's patent protection expired in the late 2000s, leading to increased biosimilar and generic competition.
Market Dynamics
-
Demand Drivers: Increasing outpatient surgeries, advancements in regional anesthesia techniques, and expanding indications support growth.
-
Pricing Trends: Since patent expiration, prices have drifted downward; however, branded formulations still command premium pricing due to formulation stability, safety profile, and hospital purchasing agreements.
Price Projections
-
Current Pricing: The average wholesale price (AWP) for a 10 mL vial of 0.25% bupivacaine is approximately $12-20, depending on purchasing volume and distribution channels.
-
Short-term Outlook (Next 2 Years): Prices are expected to stabilize or slightly decline owing to intensifying generic competition. Hospitals and clinics are increasingly switching to lower-cost alternatives, but the product remains widely used in formal surgical settings.
-
Long-term Outlook (3-5 Years): Prices may continue to decline, especially with the growth of biosimilars or generics, possibly reaching a range of $8-12 per vial. Innovation in sustained-release formulations or combination products could alter pricing dynamics.
Future Trends and Risks
-
Biosimilar Entry: Entering the market could pressure prices further, similar to trends observed with other local anesthetics.
-
Regulatory Changes: New FDA guidelines or safety alerts might influence manufacturer formulation standards and pricing.
-
Market Penetration of Alternatives: Liposomal bupivacaine (EXPAREL) and other longer-acting agents may replace traditional formulations in some settings, affecting market share and pricing.
-
Global Markets: Emerging markets show growing demand but are sensitive to price and regulatory barriers, limiting significant price increases outside developed regions.
Key Takeaways
- The drug's primary use remains stable amid expanding procedural volumes.
- Price competition from generics and biosimilars is expected to drive prices downward.
- Long-term prices may dip below current levels if biosimilars gain substantial market share.
- Innovation in drug delivery or sustained-release formulations could modify current pricing forecasts.
- Regulatory shifts and market preferences influence pricing and market share dynamics.
Frequently Asked Questions
1. What factors most significantly influence the pricing of NDC 25021-0102?
Market competition, the availability of generics or biosimilars, hospital purchasing agreements, and regulatory policies primarily influence pricing.
2. How does biosimilar competition impact the market?
Biosimilars typically enter the market at lower prices, pressuring existing prices and forcing manufacturers to adjust strategies or innovate.
3. Are there any upcoming regulatory changes that could affect this drug?
While no specific updates are imminent, FDA guidelines on compounded drugs and biosimilars can influence manufacturing and pricing strategies.
4. How will new formulations, like long-acting bupivacaine, affect the current market?
Long-acting formulations like liposomal bupivacaine may decrease demand for traditional formulations, impacting price and market share.
5. What is the outlook for pricing in emerging markets?
Prices tend to be lower due to cost sensitivity, but growth in demand can lead to moderate increases, constrained by regulatory and reimbursement structures.
References
[1] IQVIA, "Global Local Anesthetic Market Report," 2022.
[2] FDA, "Bupivacaine drug approval and safety updates," 2023.
[3] MarketWatch, "Bupivacaine Market Size and Forecast," 2022.
[4] Medscape, "Local Anesthetic Price Trends," 2023.
[5] EvaluatePharma, "Pharmaceutical Price Trends," 2022.
